Anti-hair loss composition and application thereof

Abstract

The invention belongs to the technical field of biology. The invention relates to the technical field of hair loss prevention, in particular to novel application of bakuchiol, in particular to application of bakuchiol in enhancing the hair loss prevention effect of diaminopyrimidine oxides and derivatives thereof, and the diaminopyrimidine oxides and the derivatives thereof are 2, 4-diaminopyrimidine-3-oxides, 6-(1-piperidyl)-2, 4-pyrimidine diamine-3-oxides or 6-pyrrolidinyl-2, 4-diaminopyrimidine-3-oxides. The invention relates to 2, 4-diaminopyrimidine-3-oxide.

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology. More specifically, it relates to a new use of bakuchiol, and specifically to the use of bakuchiol in enhancing the anti - hair - loss efficacy of diamino - pyrimidine oxides and their derivatives. Background Art

[0002] A large number of studies have confirmed that diamino - pyrimidine oxides can prevent hair loss and promote hair growth. They can react with sulfotransferase to generate active diamino - pyrimidine oxide sulfate, and the active sulfate component plays a role in preventing hair loss and promoting hair growth. The main principle mechanisms are as follows: (1) It promotes angiogenesis and capillary dilation, increasing the blood flow of body hair follicles to promote hair growth; (2) It stimulates the proliferation of follicular epithelial cells, improves the survival rate of scalp hair follicles, reduces follicular apoptosis, and promotes rapid hair growth; (3) It promotes the formation of hair shafts throughout the hair follicle growth phase; (4) It reduces the damage of androgens to human hair follicles, avoiding thin, soft, and falling hair; (5) It changes the trace elements in follicular cells and inhibits follicular growth. [1] 。

[0003] Bakuchiol is a natural compound extracted from Psoralea corylifolia. Its IUPAC name is (1E,3S) - 3 - vinyl - 3,7 - dimethylocta - 1,6 - diene - 4 - ol, with the molecular formula C 18 H 24 O, belonging to monoterpenoid compounds, containing a phenolic hydroxyl group (-OH) and a ketone group (C = O), and having antioxidant and anti - inflammatory properties. Its structural formula is shown as Formula 1 below. Currently, bakuchiol has been confirmed to have the following effects: ① Bakuchiol can regulate retinoic acid receptors and related downstream genes, such as CIBP1, TIG1, etc., so its efficacy and mechanism of action are very similar to those of VA; ② Bakuchiol can promote collagen production, especially the promotion effects of type I and type IV collagen are comparable to those of VA; ③ Bakuchiol can inhibit inflammatory factors and reduce inflammatory responses; ④ Bakuchiol can regulate the expression of aquaporins. In terms of the clinically verified effects, such as wrinkle removal, freckle fading, and increasing skin water content, bakuchiol not only does not lose to VA, but also has the advantage of less irritation. It is regarded as a natural substitute for retinol (vitamin A), but is milder and more stable. Currently, three domestic companies have filed for record and publicity of this raw material, namely Sytheon Corporation, Yunnan Hengjin Pharmaceutical Co., Ltd., and Guangdong Yuewei Microbiology. However, the current uses of bakuchiol are all as a skin improver, such as skin protectant, skin feel regulator, moisturizer, and antioxidant, etc. There are few studies on the application of bakuchiol in other fields.

[0004]

[0005]

[0006] [1] Xi Baohu. Research on the Synthesis Process of Diaminopyrimidine Oxide Derivatives [D]. Tianjin: Qingdao University of Science and Technology, 2023. 1-3. Summary of the Invention

[0007] Before the filing date, no potential benefits of bakuchiol on the scalp and hair had been found. However, the inventors have confirmed that although bakuchiol does not exhibit a direct hair growth-promoting effect on hair, it can enhance the anti-hair loss efficacy of diaminopyrimidine oxides. Therefore, the present invention is made based on this.

[0008] One object of the present invention is to provide the use of bakuchiol in enhancing the anti-hair loss efficacy of diaminopyrimidine oxides and their derivatives.

[0009] In one embodiment of the present invention, the diaminopyrimidine oxides and their derivatives are 2,4-diaminopyrimidine-3-oxide, 6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide, or 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide.

[0010] In addition, this enhancing effect of bakuchiol cannot be observed in other substances with anti-hair loss effects listed in the embodiments herein. These substances currently discovered include finasteride, and other substances are to be investigated.

[0011] In one embodiment of the present invention, the diaminopyrimidine oxides and their derivatives are 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide. The reason for this preference is that in the experiments, among the listed diaminopyrimidine oxides and their derivatives, the best anti-hair loss effect was observed in the combination of bakuchiol with 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide and 6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide. In the male androgenetic alopecia mouse model, the combined use of the two had the best effect, far greater than the sum of the individual uses (1 + 1 > 2), showing a synergistic effect; among the two, the combination with 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide had the best effect, and 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide has higher water solubility and lower irritation than 6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide.

[0012] Furthermore, in these combined use groups, an obvious effect of improving hair quality was observed, manifested as an obvious increase in hair diameter and an increase in the length of hair cuticles (see Figures 3 - 4 ), and this effect was weaker or even not observable in the individual use.

[0013] In one embodiment of the present invention, the weight ratio of bakuchiol to 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide is any value between 1:0.1 and 1, such as 1:0.1, 1:0.15, 1:0.2, 1:0.25, 1:0.3, 1:0.35, 1:0.4, 1:0.45, 1:0.5, 1:0.55, 1:0.6, 1:0.65, 1:0.7, 1:0.75, 1:0.8, 1:0.85, 1:0.9, 1:0.95, 1:1. In the combination of bakuchiol and 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide, satisfactory effects cannot be achieved with any arbitrary ratio. It has been experimentally confirmed that within the ratio range of 1:0.1 to 1, the two show a superimposed or synergistic effect when combined.

[0014] In one embodiment of the present invention, the weight ratio of bakuchiol to 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide is 1:0.5. Within the range of 1:0.1 to 1, when the ratio of the two is 1:0.5, the synergistic effect of preventing hair loss and improving hair quality is the strongest.

[0015] Another object of the present invention is to provide an anti-hair loss composition, which comprises bakuchiol and diaminopyrimidine oxides and their derivatives.

[0016] In one embodiment of the present invention, the diaminopyrimidine oxides and their derivatives are 2,4-diaminopyrimidine-3-oxide, 6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide or 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide.

[0017] In one embodiment of the present invention, the diaminopyrimidine oxides and their derivatives are 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide.

[0018] In one embodiment of the present invention, the weight ratio of bakuchiol to 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide is 1:0.1 to 1.

[0019] In one embodiment of the present invention, the weight ratio of bakuchiol to 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide is any value between 1:0.1 and 1, such as 1:0.1, 1:0.15, 1:0.2, 1:0.25, 1:0.3, 1:0.35, 1:0.4, 1:0.45, 1:0.5, 1:0.55, 1:0.6, 1:0.65, 1:0.7, 1:0.75, 1:0.8, 1:0.85, 1:0.9, 1:0.95, 1:1.

[0020] In one embodiment of the present invention, the weight ratio of bakuchiol to 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide is 1:0.5. In the range of 1:0.1 to 1, when the ratio of the two is 1:0.5, the synergistic effect of preventing hair loss and improving hair quality is the strongest.

[0021] In one embodiment of the present invention, the composition can be made into a medicine or a cosmetic.

[0022] Another object of the present invention is to provide an anti-hair loss essence, using bakuchiol and 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide as the main active ingredients.

[0023] In one embodiment of the present invention, in the essence, the weight ratio of bakuchiol to 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide is any value between 1:0.1 and 1, such as 1:0.1, 1:0.15, 1:0.2, 1:0.25, 1:0.3, 1:0.35, 1:0.4, 1:0.45, 1:0.5, 1:0.55, 1:0.6, 1:0.65, 1:0.7, 1:0.75, 1:0.8, 1:0.85, 1:0.9, 1:0.95, 1:1. Further, the weight ratio of bakuchiol to 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide is 1:0.5.

[0024] In one embodiment of the present invention, the anti-hair loss essence further includes other commonly used auxiliary ingredients in the art, including but not limited to: solvents, moisturizing ingredients, thickening ingredients, hair conditioning ingredients, skin conditioning ingredients, soothing ingredients, solubilizers, antioxidant ingredients, preservatives, pH regulators, and fragrances, etc.

[0025] In one embodiment of the present invention, the solvent is one of water, ethanol, denatured ethanol or a mixture thereof.

[0026] In one embodiment of the present invention, the moisturizing ingredient is one of lactic acid, arginine, sodium hyaluronate, glycerin, wild soybean oil, butylene glycol, 1,2-pentanediol, magnesium PCA, and water of Egyptian blue water lily or a mixture thereof.

[0027] In one embodiment of the present invention, the thickening ingredient is acrylate / behenyl alcohol polyether-25 methacrylate copolymer.

[0028] In one embodiment of the present invention, the hair conditioning ingredient is one of cocoyl glutamate, pyridoxine hydrochloride, safflower glucoside, methionine, and hydrolyzed wheat protein or a mixture thereof.

[0029] In one embodiment of the present invention, the skin conditioning ingredient is one or a mixture of adenosine disodium triphosphate, hybrid lavender (LAVANDULA HYBRIDA) oil, marrow squash seed oil, and watercress extract.

[0030] In one embodiment of the present invention, the soothing ingredient is one or a mixture of amaranth root extract, stearoyl glycyrrhetinate, menthol, rhamnose, and sage oil.

[0031] In one embodiment of the present invention, the solubilizer is one or a mixture of PEG-40 hydrogenated castor oil and PPG-1-PEG-9 lauryl glycol ether.

[0032] In one embodiment of the present invention, the antioxidant ingredient is one or a mixture of nasturtium extract, tocopheryl acetate, hesperidin methyl chalcone, lime oil, asiaticoside, and butylated hydroxytoluene.

[0033] In one embodiment of the present invention, the preservative is one or a mixture of sorbic acid, phenoxyethanol, and benzyl alcohol.

[0034] In one embodiment of the present invention, the pH regulator is one or a mixture of aminomethylpropanol, sodium citrate, disodium hydrogen phosphate, and citric acid. Description of the Drawings

[0035] Figure 1 Comparison of hair growth scores for each group of mice;

[0036] Figure 2 Hair coverage rate of each group of mice on the 28th day;

[0037] Among them, compared with the blank control group, * P < 0.01; compared with the model group, # P < 0.05, ## P < 0.01, ### P < 0.001; compared with the Kopexil group, a P < 0.05; compared with the minoxidil group, b P < 0.05; compared with the comparable group, c P < 0.01.

[0038] Figure 3 Comparison of hair diameters of each group of mice on the 28th day;

[0039] Figure 4 Comparison of hair cuticle lengths of each group of mice on the 28th day;

[0040] Among them, Figure 3 andFigure 4 Among them, compared with the model group, # P < 0.05, ## P < 0.01. Specific implementation manners

[0041] The present invention will be further described below in conjunction with specific embodiments, but the embodiments do not impose any form of limitation on the present invention. Unless otherwise specified, the reagents, methods, and equipment used in the present invention are conventional reagents, methods, and equipment in the technical field.

[0042] Unless otherwise specified, the reagents and materials used in the following examples are all commercially available.

[0043] Experimental Example 1. Efficacy test

[0044] 1 Experimental part

[0045] 1.1 Experimental materials: 2,4-diaminopyrimidine-3-oxide (Kopexil, purchased from Wuhan Belka Biopharmaceutical Co., Ltd.), 6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide (minoxidil, purchased from Wuhan Belka Biopharmaceutical Co., Ltd.), 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide (comparable to Rogaine, purchased from Hubei Guangao Biotechnology Co., Ltd.); bakuchiol (purchased from SYTHEON).

[0046] 1.2 Experimental methods

[0047] 1.2.1 Animal grouping and coating method: Select 110 male C57BL / 6 mice. After 1 week of environmental adaptation, they are numbered according to their body weight and then divided into 11 groups by the stratified random block design method using Excel software according to their body weight: blank control group, alopecia model group, 2wt% bakuchiol group, 1wt% Kopexil group, 1wt% minoxidil group, 1wt% comparable to Rogaine group, 1wt% finasteride group, 2wt% bakuchiol + 1wt% Kopexil group, 2wt% bakuchiol + 1wt% minoxidil group, 2wt% bakuchiol + 1wt% comparable to Rogaine group, and 2wt% bakuchiol + 1wt% finasteride group, with 10 mice in each group.

[0048] Mix rosin and paraffin in a ratio of 1:1, heat and melt them, and after cooling to a suitable temperature, evenly apply them to an area of about 4 cm × 4 cm on their backs. After cooling and solidifying and hardening, peel them off to induce the hair follicles of the mice to enter the growth phase. At this time, there is no difference in morphology between the hair follicles and the spontaneously formed hair follicles in the growth phase, and the skin is pink. On the second day after hair removal, anesthetize the mice. In the blank group, apply a 50% ethanol solution at 0.1 mL·cm -2 Once a day for 28 consecutive days; the mice in the remaining groups were all smeared with a mass concentration of 1 mg·mL -1Testosterone solution, once a day for 28 consecutive days. After modeling for 30 minutes every day, in the blank group and the model group, the matrix solution was applied externally to the depilated area of the mice with a cotton swab, and in the remaining drug groups, the corresponding drug solutions were applied externally. The administration volume was 0.2 mL per mouse.

[0049] 1.2.2 Preparation of the medicinal solution: ① Matrix solution: Weigh 95% ethanol, propylene glycol, and pure water by volume and mix them thoroughly according to a mass ratio of 3:6:2 to obtain the matrix solution; ② Bakuchiol group, Kopexil group, Minoxidil group, Cebipil group, and Finasteride group: Weigh the corresponding weights of the drugs and dissolve them evenly in the matrix solution to obtain the medicinal solutions; ③ Combined group: Weigh the corresponding weights of the drugs and dissolve them separately in the matrix solution to obtain the medicinal solutions of 2 wt% bakuchiol + 1 wt% Kopexil, 2 wt% bakuchiol + 1 wt% minoxidil, 2 wt% bakuchiol + 1 wt% cebipil, and 2 wt% bakuchiol + 1 wt% finasteride.

[0050] 1.2.3 Measurement of hair growth rate: Observe the changes in the skin color and hair growth of the mice, take photos after anesthesia on the 0th day, 7th day, 14th day, 21st day, and 28th day, and score the hair regrowth of each mouse according to the following Table 1 with reference to the scoring criteria and combined with the actual situation.

[0051] Table 1 Scoring criteria for hair growth

[0052] Score Scoring Criteria 1 The skin is pink, which is the state when the hair has just been removed. The red color is more obvious, and at this time, the hair follicles are in the resting phase 2 The skin is pinkish-white, the red color is not obvious, but no gray color is seen yet. At this time, the hair follicles begin to enter the early growth stage 3 The skin is white, obvious gray color appears, but no black color is seen yet. At this time, the hair follicles are in the early growth stage 4 The skin is gray, and it is locally blackened. Short hairs are occasionally seen. At this time, the hair follicles are in the middle growth stage 5 The skin is dark gray and covered with short hairs. At this time, the hair follicles are in the middle and late growth stage; 6 points It indicates that the skin is covered with long black hairs. At this time, the hair follicles are in the late growth stage

[0053] According to the above scoring criteria, three people scored the hair growth of the mice respectively, and the average value was taken as their final score. On the 28th day, use the software Image J to measure the hair coverage area and the depilated area of the mice in the depilated area, and calculate according to the following formula.

[0054] Hair coverage rate (%) = Hair coverage area / Depilated area × 100%

[0055] 1.2.3 Measurement of hair length: Sacrifice the mice on the 29th day, randomly pluck 3 tufts of newly grown hair (the number of hairs > 20) from the depilated area with forceps, select the longest 20 hairs after spreading them on white paper, and measure them with a vernier caliper respectively to record the average length of the newly grown hair of the mice.

[0056] 1.2.4 Measurement of hair quality: Randomly select the newly grown hair in the depilated area, take a photo with a scanning electron microscope (SEM), use Image J to measure the middle diameter of the hair in the picture to evaluate the hair thickness, and measure the length of the hair cuticle in the middle of the hair to evaluate the size of the hair cuticle, and comprehensively evaluate the quality of the newly grown hair of the mice.

[0057] 1.2.5 Detection of the number of skin hair follicles by HE staining: After the mice were sacrificed, the skin in the depilated area was cut off and placed in 4% paraformaldehyde tissue fixative for at least 24 hours. After dehydration, paraffin embedding, sectioning, dehydration, hematoxylin-eosin staining, and sealing were carried out. The results were observed and recorded under an optical microscope (×100). Using the counting function of Image J, the number of hair follicles in the HE-stained pictures of each group was counted. Six fields of view were taken for each group, and then the average value was calculated.

[0058] 2 Results and Discussion

[0059] 2.1 Hair growth rate

[0060] The scores of hair growth in the depilated area of mice in each group are shown in Figure 1 , and the hair coverage rate is shown in Figure 2 . It can be analyzed that compared with the blank group, the hair growth in the model group became significantly slower, and the difference in growth rate became gradually obvious on the 14th day. Compared with the model group, the hair growth rates of mice in the Kopexil group, minoxidil group, Kobelo group, and finasteride group were significantly faster. In the combined group, except for the combination of bakuchiol + finasteride, the hair growth rates of mice in the other groups were higher than those when used alone, and the difference was significant. This indicates that bakuchiol can enhance the hair growth-promoting effects of Kopexil, minoxidil, and Kobelo.

[0061] 2.2 Hair length and number of hair follicles

[0062] As can be seen from the following table, the hair length and the number of hair follicles of mice in each group of the model group were significantly reduced compared with the blank control group (P < 0.01); compared with the model group, the hair length and the number of hair follicles in the bakuchiol group increased, but there was no significant difference. However, the hair length and the number of hair follicles of mice in the Kopexil, minoxidil, Kobelo, and finasteride groups increased significantly or extremely significantly compared with the model group; in the combined group, except for the finasteride group, the hair length and the number of hair follicles of mice in the other groups were extremely significantly higher than those in the single-use group, and the difference was significant. Especially in the bakuchiol + Kobelo group and the bakuchiol + minoxidil group, the combined effect of the two was much greater than the sum of the single use (1 + 1 > 2), showing a synergistic effect.

[0063] Table 2 Hair length and number of hair follicles

[0064]

[0065]

[0066] Compared with the blank group, ** P < 0.01; compared with the model group, # P < 0.05, ## P < 0.01; compared with the Kopexil group,a P < 0.05; compared with the minoxidil group, b P < 0.01; compared with the copexil group, c P < 0.01.

[0067] 2.3 Hair quality

[0068] The comparison of hair diameters in the hair removal areas of mice in each group is shown in Figure 3 , and the comparison of cuticle lengths is shown in Figure 4 , there were no significant differences in hair diameters and cuticle lengths of mice in the model group, Kopexil group, minoxidil group, copexil group, and finasteride group compared with the blank group. However, the hair diameters of mice in the bakuchiol group and the combined bakuchiol group were significantly increased, and the cuticle lengths were increased. This indicates that bakuchiol can not only enhance the effect of promoting hair growth by diaminopyrimidine oxides, but also improve the quality of the newly grown hair.

[0069] Experimental Example 2: Verification of the hair growth promoting effects of bakuchiol and copexil with different mass ratios

[0070] After verification in Experimental Example 1, it was found that the combined anti - hair loss effect of bakuchiol and copexil was the best. Further, referring to the method of Experimental Example 1, the effects of different ratios of bakuchiol and copexil on the hair growth rate and hair follicle number in the male androgenetic alopecia mouse model were investigated, and the results are shown in Table 3 below.

[0071] Table 3 Experimental results

[0072] Group Hair Length (mm) Average Number of Hair Follicles Hair Coverage Rate (%) Blank Control Group 6.562±0.438 49.67±1.75 90.36±8.68 Model Group <![CDATA[4.351±0.215 ** > <![CDATA[19.83±2.32 ** > <![CDATA[31.46±2.37 ** > Bakuchiol Group 4.482±0.304 20.91±1.35 33.18±3.25 Kepirox Group <![CDATA[4.729±0.221 # > <![CDATA[24.50±2.11 ## > <![CDATA[55.29±5.23 ## > Bakuchiol + Kepirox (1:0.1) <![CDATA[5.347±0.115 ^ > <![CDATA[31.00±1.06 ^ > <![CDATA[70.15±3.92 ^^ > Bakuchiol + Kepirox (1:0.2) <![CDATA[5.564±0.136 ^^ > <![CDATA[32.83±1.33 ^ > <![CDATA[72.27±2.08 ^^ > Bakuchiol + Kepirox (1:0.5) <![CDATA[6.262±0.442 ^^ > <![CDATA[46.00±1.28 ^^ > <![CDATA[83.48±5.33 ^^ <!-- 6 -->]]> Bakuchiol + Kepirox (1:0.7) <![CDATA[6.041±0.259 ^^ > <![CDATA[41.00±1.53 ^^ > <![CDATA[81.05±4.39 ^^ > Bakuchiol + Kepirox (1:1) <![CDATA[5.734±0.226 ^^ > <![CDATA[36.33±1.21 ^^ > <![CDATA[78.55±3.05 ^^ > Bakuchiol + Kepirox (0.1:1) <![CDATA[5.156±0.186 ^ > <![CDATA[28.17±2.03 ^ > <![CDATA[62.44±1.97 ^ > Bakuchiol + Kepirox (0.2:1) <![CDATA[5.123±0.371 ^ > <![CDATA[29.67±1.32 ^ > <![CDATA[65.37±3.55 ^ > Bakuchiol + Kepirox (0.5:1) <![CDATA[5.329±0.105 ^ > <![CDATA[32.17±2.11 ^ > <![CDATA[74.40±4.16 ^^ > Bakuchiol + Kepirox (0.7:1) <![CDATA[5.557±0.244 ^^ > <![CDATA[33.83±1.59 ^ > <![CDATA[75.29±4.03 ^^ >

[0073] Compared with the blank group, ** P < 0.01; compared with the model group, # P < 0.05, ## P < 0.01; compared with the copexil group, ^ P < 0.05, ^^ P < 0.01.

[0074] The above - mentioned embodiments are preferred embodiments of the present invention. However, the embodiments of the present invention are not limited by the above - mentioned embodiments. Any other changes, modifications, substitutions, combinations, and simplifications made without departing from the spirit and principle of the present invention shall be equivalent replacement methods and are all included in the protection scope of the present invention.

Claims

1. Use of bakuchiol in enhancing the anti-hair loss effect of diaminopyrimidine oxides and their derivatives.

2. The use according to claim 1, characterized in that The diaminopyrimidine oxide and its derivatives are 2,4-diaminopyrimidine-3-oxide, 6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide or 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide.

3. The use according to claim 2, characterized in that: The diaminopyrimidine oxide and its derivatives are 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide.

4. The use according to claim 3, characterized in that: The weight ratio of bakuchiol to 6-pyrrolidino-2,4-diaminopyrimidine-3-oxide is 1:0.1-1.

5. The use according to claim 4, characterized in that The weight ratio of bakuchiol to 6-pyrrolidino-2,4-diaminopyrimidine-3-oxide is 1:0.

5.

6. An anti-hair loss composition, characterized in that: The composition comprises bakuchiol and diaminopyrimidine oxides and derivatives thereof.

7. The composition according to claim 6, characterized in that The diaminopyrimidine oxide and its derivatives are 2,4-diaminopyrimidine-3-oxide, 6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide or 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide.

8. The preparation according to claim 7, characterized in that The diaminopyrimidine oxide and its derivatives are 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide.

9. An anti-hair loss essence, characterized in that: Bakuchiol and 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide are the main active ingredients.

10. The anti-hair loss essence according to claim 9, characterized in that: In the essence, the weight ratio of bakuchiol to 6-pyrrolidinyl-2,4-diaminopyrimidine-3-oxide is 1:0.1-1.

Images